Feature | February 17, 2011| Dave Fornell

Cardiovascular Trends to Watch in 2011

Based on my observations and the devices that caught the eye of the doctors on the Diagnostic & Interventional Cardiology Editorial Advisory Board, we created the following predictions of what will be hot trends to watch in 2011. These were some of the big topics and new technologies highlighted at the Transcatheter Cardiovascular Therapeutics (TCT) symposium in September, and the American Heart Association (AHA) and the Radiological Society of North America (RSNA) meetings in November.

Percutaneous valves: These devices are now a reality in Europe and will be coming to the U.S. market shortly. The first results from the U.S. PARTNER trial presented at TCT for the Edwards Sapien aortic valve were very positive. In December, Medtronic began its first U.S. implants of the CoreValve aortic valve as part of the U.S. pivotal trial.

Robotics in the cath lab: The Davinci system has made a dramatic impact on urologic practice and Stereotaxis and Hansen are vying for the electrophysiology market. The first in-human study of the robotically assisted percutaneous coronary intervention system demonstrated that the technique is safe and feasible. The results of the study of the CorPath 200, by Corindus Vascular Robotics, were presented at TCT. The system allows interventional cardiologists to sit down without radiation protection and remotely manipulate catheters, wires, balloons and stents from the control booth.

Advanced cath lab imaging: The introduction of rotational angiography in the cath lab with a rapid rotation of the imaging arm creates dynamic CT-like 3-D imaging, which can be used as an overlay with routine angiographic imaging. The technology allows for real-time CT superimposition, allowing for more accurate endovascular work and might become a routine part of any endovascular suite. This type of technology might also be useful at defining physiology, such as ischemia. Other advances include improved hybrid overlay images from various imaging modalities and live angiography for better transcatheter navigation.

Percutaneous renal nerve ablation: This was discussed as a new treatment to reduce blood pressure. Data from Ardian’s Symplicity HTN-2 trial of its renal ablation catheter was presented at AHA. It showed after six months, patients treated with Ardian’s device experienced an average drop in blood pressure of 32/12 mmHg compared to an increase in blood pressure of 1/0 mmHg in the control group of patients treated with medical therapy alone.

Left atrial appendage (LAA) occlusion devices: These transcatheter occluders are designed to prevent atrial fibrillation-induced emboli and replace the current standard of warfarin therapy. The CoHerex WaveCrest has an improved design over previous devices that have been tested and is entering first-in-man trials in 2011.

iPad integration of picture archiving and communication systems (PACS): Healthcare software vendors are introducing a large variety of new apps for the iPad, including advanced visualization software and access to PACS and cardiac reporting software. The iPad frees clinicians from their desktop computer and allows them to work from any location with Internet access. The small size of the device means it can be carried around like the traditional clipboard, but offers all the functionality of their primary computer workstation.

PET/MRI: The first two combined positron emission tomography/magnetic resonance imaging (PET/MRI) systems were introduced at RSNA by Philips and Siemens. These systems have the potential to greatly reduce radiation dose by eliminating CT scans in hybrid imaging, which have been used for attenuation correction and for an anatomical overlay to the PET metabolic imaging. Both systems are pending FDA clearance.

3-D hearts in motion: Advanced visualization can make pretty pictures of 3-D anatomy, but in the case of the heart, it has so far failed to show functionality and natural movement during the cardiac cycle. Using supercomputing algorithms, Ziosoft developed the PhyZiodynamic software to take a CT or MRI data set of a cardiac cycle and put it into motion. The software allows a full 3-D rendering of a heart in motion that can be sliced through and rotated on any axis. It also has an option to show a color-coded tissue strain map.

Related Content

NCDR, ACC, JACC, American College of Cardiology, national trends, heart disease treatments, trends in cardiovascular care
News | Cath Lab| January 23, 2017
January 23, 2017 — Over 93 percent of heart attack patients are receiving stents within the guideline-recommended thr
Apollo Enterprise Imaging, DiACardio, Enterprise Patient Multimedia Manager, EPMM, LVivo Toolbox
Technology | Clinical Decision Support| January 19, 2017
January 19, 2017 — Apollo Enterprise Imaging Corp.
Materialise, AnatomyPrint, 3-D printing service, RSNA 2016, RSNA 2017, Carestream
Technology | 3-D Printing| January 19, 2017
Materialise NV has launched AnatomyPrint, an easy-to-use service for medical professionals that delivers 3-D printed...
Synergy stent, abluminal polymer DES, bioresorbable polymer DES, bioresorbable polymer metallic stent

The Synergy stent is the first FDA cleared drug-eluting stent to use a bioresorbable polymer drug carrier. When the polymer dissolves after about four months, the devices become a bare metal stent. The technology is supposed to reduce the rate of late stent thrombosis due to vessel inflammation caused by durable polymers.

Feature | Stents Bioresorbable| January 17, 2017 | Dave Fornell
One of the big advancements in drug-eluting stent (DES) technology has been the development of bioresorbable polymers
St. Jude Medical, Amplatzer Amulet LAA Occluder, observational study, TCT 2016
News | Left Atrial Appendage (LAA) Occluders| November 03, 2016
St. Jude Medical Inc. presented favorable results from the largest observational study to date of the company’s...
Medtronic, CoreValve Evolut R TAVR system, U.S. IDE Study, TCT 2016
News | Heart Valve Technology| November 03, 2016
Medtronic plc unveiled new clinical data showing that patients treated with the self-expanding CoreValve Evolut R...
congenital heart patients, cardiac cath lab, anesthesia sedation practices, joint document, SCAI, SPA, CCAS
News | Congenital Heart| November 03, 2016
The Society for Cardiovascular Angiography and Interventions (SCAI), the Society for Pediatric Anesthesia (SPA) and the...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
SENTINEL trial, transcatheter embolic protection, TCEP, TAVR, stroke, TCT 2016
News | Embolic Protection Devices| November 03, 2016
An international study has found that transcatheter cerebral embolic protection (TCEP) is safe, provides effective...
News | Drug-Eluting Balloons| November 03, 2016
The Spectranetics Corp. announced that it has submitted to the U.S. Food & Drug Administration (FDA) its Pre-Market...
Overlay Init